Impact of the 2020 China Diabetes Society Guideline on the Prevalence of Diabetes Mellitus and Eligibility for Antidiabetic Treatment in China

Shi, Guoshuai; Zhu, Ni; Qiu, Lin; Hong, Yan; Zeng, Lingxia; Wang, Duolao; Dang, Shaonong; Li, Zhaoqing; Kang, Yijun; Chen, Tao; Li, Chao

doi:10.2147/ijgm.s331948

Cited by 10 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among all countries for which data are available, China has the highest number of adults with diabetes, and it is anticipated that it will remain in this position until at least 2045 [ 1 ]. Applying the diagnostic criteria for diabetes suggested by the American Diabetes Association (ADA), the data from two national representative epidemiological surveys in China showed that the prevalence of diabetes regardless of type went up from 10.9% in 2013 to 13.2% in 2020 [ 39 , 40 ].…”

Section: Local Aspects/experiencementioning

confidence: 99%

Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

For decades, self-monitoring of blood glucose (SMBG) has been considered a cornerstone of adequate diabetes management. Structured SMBG can follow different monitoring patterns, and it results in improved glycemic control, reduced hypoglycemia, and a better quality of life of people with diabetes. The technology, usability, and accuracy of SMBG systems have advanced markedly since their introduction a few decades ago. Current SMBG systems are small and easy to use, require small (capillary) blood sample volumes, and provide measurement results within seconds. In addition, devices are increasingly equipped with features such as connectivity to other devices and/or digital diaries and diabetes management tools. Although measurement quality can come close to or equal that of the glucose monitoring systems used by healthcare professionals, several available SMBG systems still do not meet internationally accepted accuracy standards, such as the International Organization for Standardization 15197 standard. Reports from China, India, and Brazil based on local experience suggest that in addition of the accuracy issues of SMBG systems, other obstacles also need to be overcome to optimize SMBG usage. Nonetheless, adequate usage of SMBG data is of high relevance for the management of people with type 2 diabetes mellitus. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-022-01254-8.

show abstract

Section: Local Aspects/experiencementioning

confidence: 99%

Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…2 The Chinese Diabetes Society guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin as the treatment options for patients with poor glycaemic control with first-line oral antihyperglycaemic drugs (OADs). 3 Still, insulin has some limitations, such as the risk of hypoglycaemia and increased body weight. 1,4,5 The gastrointestinal side effects of GLP-1 RAs often lead to intolerability and subsequently a high discontinuation rate.…”

Section: Introductionmentioning

confidence: 99%

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

Yang

Zhang

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: To evaluate the efficacy of iGlarLixi in the Asian Pacific (AP) population with type 2 diabetes (T2D) using derived time-in-ranges calculated from seven-point selfmeasured blood glucose.Methods: Two phase III trials were analysed. LixiLan-O-AP was performed in insulinnaive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi). LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar. Changes in derived time-in-ranges from baseline to end-oftreatment (EOT) and estimated treatment differences (ETDs) were analysed. The proportions of patients achieving 70% or higher derived time-in-range (dTIR), 5% or higher dTIR improvement, and the composite triple target (≥ 70% dTIR, < 4% derived time-below-therange [dTBR] and < 25% derived time-above-the-range [dTAR]) were calculated. Results:The changes from baseline to EOT in dTIR with iGlarLixi were greater versus iGlar (ETD 1 : 11.45% [95% CI, 7.66% to 15.24%]) or Lixi (ETD 2 : 20.54% [95% CI, 15.74% to 25.33%]) in LixiLan-O-AP, and versus iGlar (ETD: 16.59% [95% CI, 12.09% to 21.08%]) in LixiLan-L-CN. In LixiLan-O-AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%). In LixiLan-L-CN, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT were 71.4% and 59.8% with iGlarLixi, greater than with iGlar (45.4% and 39.5%). More patients achieved the triple target with iGlarLixi compared with iGlar or Lixi. Conclusion: iGlarLixi achieved greater improvements in dTIR parameters versus iGlaror Lixi in insulin-naïve and insulin-experienced AP people with T2D.

show abstract

“…According to the latest version of the Diabetes Map released by the International Diabetes Federation (IDF), 537 million adults (ages 20-79) suffer from diabetes, and the number of diabetes patients in the world will reach 783 million by 2045. 1,2 However, the existing hypoglycemic drugs developed based on a single target and single pathway have many problems, such as gastrointestinal discomfort, hypoglycemia, weight gain, impaired liver and kidney function, blood glucose drift, etc. 3 Recently, the interaction between gut microbiota and host metabolism has become a focus, and it has also brought new ideas for the treatment of metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver.…”

Section: Introductionmentioning

confidence: 99%

Hypoglycemic effect of the polysaccharides fromAstragalus membranaceuson type 2 diabetic mice based on the “gut microbiota–mucosal barrier”

Chen

2022

Food Funct.

View full text Add to dashboard Cite

show abstract

Impact of the 2020 China Diabetes Society Guideline on the Prevalence of Diabetes Mellitus and Eligibility for Antidiabetic Treatment in China

Cited by 10 publications

References 21 publications

Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus

Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

Hypoglycemic effect of the polysaccharides fromAstragalus membranaceuson type 2 diabetic mice based on the “gut microbiota–mucosal barrier”

Contact Info

Product

Resources

About